ISSUE 1500
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved Jentadueto XR (Boehringer Ingelheim/Lilly), a once-daily extended-release formulation of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the biguanide metformin, for oral treatment of type 2 diabetes. Linagliptin and metformin have been available for years in a twice-daily immediate-release combination (Jentadueto).1 Once-daily extended-release formulations combining metformin with the DPP-4 inhibitors saxagliptin (Kombiglyze XR) and sitagliptin (Janumet XR) are also available.2
CLINICAL STUDIES — No new trials were required for approval of Jentadueto XR, which was based on earlier trials of linagliptin coadministered with metformin. Taking immediate-release linagliptin and metformin together has been shown to reduce A1C by an additional 0.5-1.1% compared to taking
... more- Linagliptin/metformin (Jentadueto) for type 2 diabetes. Med Lett Drugs Ther 2012; 54:37.
- Drugs for type 2 diabetes. Treat Guidel Med Lett 2014; 12:17.
- T Haak et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012; 14:565.
- MR Taskinen et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13:65.
- In brief: New recommendations for use of metformin in renal impairment. Med Lett Drugs Ther 2016; 58:51.

Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1500b
Electronic, downloadable article - $45